Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457098 | 0.89 | SCN9A (0.46) | SLC6A4SLC6A2SLC6A3HTR2ASCN9A | |
| SCHEMBL29457101 | 0.84 | LPAR1 (0.39) | SCN9A | |
| SCHEMBL29457021 | 0.84 | SCN4A (0.46) | SCN9A | |
| SCHEMBL29457351 | 0.82 | SCN9A (0.38) | SLC6A4HTR2ASCN9A | |
| SCHEMBL29457068 | 0.79 | SCN9A (0.45) | SCN9A | |
| SCHEMBL29457553 | 0.77 | SCN9A (0.38) | SCN9A | |
| SCHEMBL27211110 | 0.76 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL29457033 | 0.75 | APLNR (0.34) | SCN9A | |
| SCHEMBL29457093 | 0.75 | SCN9A (0.48) | SCN9A | |
| SCHEMBL29457075 | 0.73 | CARM1 (0.42) | SCN9ASOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225746-A1 | MRGX2 ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-08-16 | — | — | EP | claimed |
| WO-2022073904-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | claimed |
| WO-2022073904-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |